Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP53-EphA-2-CAR-DC vaccine plus ICIs in advanced tumors
NCT05631886Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Whole Cell Cancer Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TP53-EphA-2-CAR-DC in solid tumor and lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment related adverse events at 2 years, Clinical Response at 2 years and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
TP53-EphA-2-CAR-DC
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05631886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631886.